Abstract
Low dose cholestyramine ('Questran A') and colestipol ('Colestid Orange') were compared in a blinded two period crossover study of 55 patients attending a hospital lipid clinic. Colestipol was rated higher on a combined acceptability/palatability score. Both treatments reduced low density lipoprotein (LDL) cholesterol to a similar extent.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Betteridge D. J., Dodson P. M., Durrington P. N., Hughes E. A., Laker M. F., Nicholls D. P., Rees J. A., Seymour C. A., Thompson G. R., Winder A. F. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J. 1993 May;69(811):359–369. doi: 10.1136/pgmj.69.811.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brown G., Albers J. J., Fisher L. D., Schaefer S. M., Lin J. T., Kaplan C., Zhao X. Q., Bisson B. D., Fitzpatrick V. F., Dodge H. T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990 Nov 8;323(19):1289–1298. doi: 10.1056/NEJM199011083231901. [DOI] [PubMed] [Google Scholar]
- Hills M., Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979 Jul;8(1):7–20. doi: 10.1111/j.1365-2125.1979.tb05903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]